Verastem Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Für Verastem wird ein Gewinn- und Umsatzwachstum von 41.7% bzw. 37.8% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 49.5% pro Jahr steigen soll.

Wichtige Informationen

41.7%

Wachstumsrate der Gewinne

49.54%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.2%
Wachstumsrate der Einnahmen	37.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Aug 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...

Recent updates

Narrative-Update • Aug 10

VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space

Verastem's analyst fair value estimate has moved from $20.00 to $18.00 as analysts recalibrate their models and lower price targets in light of recent Q1 and Q2 updates and a more crowded competitive field. Analyst Commentary Recent Street research on Verastem shows a cluster of lower price targets following Q1 and Q2 updates, yet many bullish analysts are maintaining positive views on the stock.

Narrative-Update • Jun 26

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

The Verastem analyst price target has been revised lower, with a fair value estimate moving from about $14.00 to about $8.85 as analysts factor in a less favorable long thesis in a more crowded competitive space and updated post-earnings models. Analyst Commentary on Verastem Recent Street research on Verastem reflects a more cautious tone, with several bearish analysts trimming their fair value assumptions and reassessing the long thesis after recent earnings and competitive updates.

Analyseartikel • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...

Neues Narrative • Jan 22

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

Catalysts About Verastem Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer. What are the underlying business or industry changes driving this perspective?

Analyseartikel • Dec 26

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem, Inc. ( NASDAQ:VSTM ) shareholders won't be pleased to see that the share price has had a very rough month...

Seeking Alpha • Jul 16

Verastem: The Market Is Ignoring The Progress

Summary FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point. I maintain a 3/5 conviction, plan to add to my position below $5.75, and aim to hold long-term as VSTM targets KRAS-driven cancers. Read the full article on Seeking Alpha

Seeking Alpha • May 26

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Summary Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical trial results show a significant drop in response rates, suggesting less robust efficacy than earlier believed. Financially, Verastem has only a year of cash runway and faces significant dilution risks to extend it. Downgrade the recommendation to 'hold' due to increased risks and market volatility associated with microcap stocks. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:VSTM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	260	-114	-98	-90	7
12/31/2027	181	-157	-150	-145	8
12/31/2026	116	-166	-166	-162	9
6/30/2026	88	-203	-172	-162	N/A
3/31/2026	50	-194	-161	-151	N/A
12/31/2025	31	-209	-147	-138	N/A
9/30/2025	13	-241	-141	-133	N/A
6/30/2025	2	-167	-120	-120	N/A
3/31/2025	10	-149	-115	-115	N/A
12/31/2024	10	-131	-105	-105	N/A
9/30/2024	10	-93	-109	-109	N/A
6/30/2024	10	-89	-102	-102	N/A
3/31/2024	N/A	-106	-95	-94	N/A
12/31/2023	N/A	-87	-86	-86	N/A
9/30/2023	N/A	-77	-73	-73	N/A
6/30/2023	N/A	-75	-72	-72	N/A
3/31/2023	N/A	-73	-65	-65	N/A
12/31/2022	3	-74	-64	-64	N/A
9/30/2022	3	-73	-57	-57	N/A
6/30/2022	3	-78	-53	-53	N/A
3/31/2022	4	-73	-53	-53	N/A
12/31/2021	2	-71	-54	-54	N/A
9/30/2021	2	-75	-65	-65	N/A
6/30/2021	81	-39	-10	-10	N/A
3/31/2021	84	-45	-19	-19	N/A
12/31/2020	89	-68	-34	-34	N/A
9/30/2020	92	-87	-49	-49	N/A
6/30/2020	22	-130	-122	-122	N/A
3/31/2020	21	-149	N/A	-134	N/A
12/31/2019	17	-149	N/A	-139	N/A
9/30/2019	15	-122	N/A	-120	N/A
6/30/2019	22	-113	N/A	-115	N/A
3/31/2019	28	-89	N/A	-91	N/A
12/31/2018	27	-72	N/A	-75	N/A
9/30/2018	26	-79	N/A	-76	N/A
6/30/2018	10	-81	N/A	-65	N/A
3/31/2018	N/A	-76	N/A	-69	N/A
12/31/2017	N/A	-68	N/A	-57	N/A
9/30/2017	N/A	-61	N/A	-43	N/A
6/30/2017	N/A	-46	N/A	-37	N/A
3/31/2017	N/A	-41	N/A	-29	N/A
12/31/2016	N/A	-36	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-44	N/A	-39	N/A
3/31/2016	N/A	-51	N/A	-45	N/A
12/31/2015	N/A	-58	N/A	-46	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VSTM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VSTM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VSTM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VSTMDie Einnahmen des Unternehmens (37.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.9% pro Jahr).

Hohe Wachstumseinnahmen: VSTMDie Einnahmen des Unternehmens (37.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VSTM in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/08/20 22:35
Aktienkurs zum Tagesende	2026/08/20 00:00
Gewinne	2026/06/30
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Verastem, Inc. wird von 29 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Matthew Cross	Alliance Global Partners
James Molloy	Alliance Global Partners
Matthew Venezia	Alliance Global Partners

Verastem Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 14%, EPS downgraded

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

Forecast to breakeven in 2028

Forecast to breakeven in 2028

Consensus EPS estimates fall by 13%

Consensus revenue estimates increase by 20%

Recent updates

Consensus revenue estimates increase by 14%, EPS downgraded

VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space

New major risk - Financial position

New minor risk - Financial position

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem, Inc. to Report Q2, 2026 Results on Aug 06, 2026

New minor risk - Share price stability

New minor risk - Insider selling

Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000 Value Benchmark

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

Verastem Oncology Demonstrates Clinical Activity of Vs-7375 in Target-D 101 Phase 1/2 Clinical Trial in Patients with Advanced Kras G12d-Mutated Solid Tumors

Verastem Inc Announces Positive Updated Safety and Efficacy Results from Ramp 205 Phase 1B 2A Trial of Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab Paclitaxel in First Line Mpdac

Insufficient new directors

Verastem, Inc. Announces Board Changes

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

Verastem, Inc. to Report Q1, 2026 Results on May 07, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy

Verastem, Inc., Annual General Meeting, May 21, 2026

New minor risk - Profitability

Forecast to breakeven in 2028

Verastem, Inc. to Report Q4, 2025 Results on Mar 04, 2026

Forecast to breakeven in 2028

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

President recently sold US$74k worth of stock

Insufficient new directors

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem Oncology Announces Management Changes

President notifies of intention to sell stock

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $89.99962 million.

Consensus EPS estimates fall by 13%

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2A Dose Escalation Trial of Vs-7375, an Oral Kras G12d (On/Off) Inhibitor, in Patients with Kras G12d Mutant Solid Tumors

Verastem, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 20%

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Verastem Oncology Grants Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Consensus revenue estimates decrease by 11%

Verastem: The Market Is Ignoring The Progress

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Consensus revenue estimates fall by 28%

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-In-Human Phase 1 FRAME Study of Avutometinib in Solid Tumors, Including Low-Grade Serious Ovarian Cancer

President recently sold US$91k worth of stock

New minor risk - Profitability

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/Off) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375) Inhibitor

Price target increased by 18% to US$15.75

Verastem Oncology Announces Positive Updated Results from Ramp 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-Of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Verastem, Inc. Announces that FDA Approves AVMAPKI FAKZYNJA for Treating KRAS-mutated Ovarian Cancer

Verastem, Inc. announced that it expects to receive $75.004271 million in funding

Verastem, Inc., Annual General Meeting, May 22, 2025

Verastem, Inc. Auditor Raises 'Going Concern' Doubt

Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer

Verastem, Inc. announced that it has received $75 million in funding

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has filed a Follow-on Equity Offering.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers